
Docket No.: ACADIA.011DV1



INFORMATION DISCLOSURE STATEMENT

Andersson, et al.

App. No

10/623,119

Filed

July 17, 2003

For

MUSCARINIC AGONISTS

Examiner

Chang, Celia c.

Art Unit

1625

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 17, 2006

(Date)

Ryan E. Melnick, Reg. No. 58,621

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 11 references to be considered by the Examiner. Also enclosed are 4 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note that cite Number 12, CHEVOLOT, et al., is of record in U.S. patent application No. 09/844,685, filed April 27, 2001, which is the parent of this application. A Copy of this reference is not being submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11-17-06

11/22/2006 RMEBRAHT 00000018 10623119

02 FC:1806

180.00 OP

Ryan E. Melnick

Registration No. 58,621 Attorney of Record

Customer No. 20,995

(619) 235-8550

3035698 111706

INFORMATION DISCLOSURE
STATEMENT BY APPLICANE

(Multiple sheets used when necessary)
SHEET 1 OF 1 NOV 2 1 2006

	F TO/3B/08 Equivalent
Application No.	10/623,119
Filing Date	July 17, 2003
First Named Inventor	Andersson, et al.
Art Unit	1625
Examiner	Chang, Celia C.
Attorney Docket No.	ACADIA.011DV1

U.S. BETENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	3,412,097	11/19/1968	Gerardus, J.B., Corts	
	2	5,707,798	01-13-1998	Brann, Mark	
	3	5,912,132	06-15-1999	Acadia Pharmaceuticals	
	4	5,955,281	09-21-1999	Brann, Mark,	
	5	6,566,364	05-20-2003	Pelgion, et al.	
	6	2001-0034352	10-25-2001	Pelgion, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т¹
	7	EP 0511610	11-04-1992	Hoechst-Roussel		
	8	EP 0091512	10/19/1983	Hoechst-Roussel		
	9	WO 98/04546	02/05/1998	Synthelab		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	10	BRITTON, et al. "Structure-Activity Relationships of a Series of Benzothiophenederived NPY Y1 Anatagonists: Optimization of the C-2 Side Chain" Bioorganic & Medicinal Chemistry Letters 9, (1999) 475-480.		
	11	CHEVOLOT, et al. "Indoles, XI Synthesis of Dl" CA 84: 31279 (1975)		

3027843 111706

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.